# BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

> **NCT00040755** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 68 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Bone Metastases
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** rebimastat
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00040755
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040755, "BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00040755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*